Literature DB >> 23390036

Antidepressant use and new-onset diabetes: a systematic review and meta-analysis.

Sandipan Bhattacharjee1, Rituparna Bhattacharya, George A Kelley, Usha Sambamoorthi.   

Abstract

Antidepressant use has been linked to new-onset diabetes. However, the existing literature on this relationship has yielded inconsistent findings. The primary objective of this study was to systematically synthesize the literature on the relationship between antidepressant use and new-onset diabetes using meta-analysis. A systematic literature search was conducted to identify relevant studies in seven electronic databases. Two independent reviewers identified the final list of studies to be included in the meta-analysis using a priori selection criteria. Results for the primary outcome of interest, that is, odds and hazards of developing new-onset diabetes, were pooled using a random-effects model. Egger's regression test and the Trim and Fill method were utilized to detect the presence of any potential publication bias. Sensitivity analysis was conducted using the leave-one-out method as well as individual categories of antidepressant drugs. Eight studies met the inclusion criteria. Random effects models revealed that adults with any use of antidepressants were more likely to develop new-onset diabetes compared with those without any use of antidepressants [odd ratios = 1.50, 95% confidence interval (CI), 1.08-2.10; hazards ratio = 1.19, 95% CI, 1.08-1.32]. Sensitivity analyses revealed fair robustness; selective serotonin reuptake inhibitors and tricyclic antidepressants were more likely to be associated with the development of new-onset diabetes. Results from the Egger's regression test and Trim and Fill method revealed no evidence of publication bias. Among adults, antidepressant use was associated with higher chances of new-onset diabetes. However, because a cause-and-effect relationship cannot be established by observational studies, future randomized controlled studies are needed to confirm this association.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390036      PMCID: PMC4888867          DOI: 10.1002/dmrr.2393

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  40 in total

1.  STAR*D: what have we learned?

Authors:  A John Rush
Journal:  Am J Psychiatry       Date:  2007-02       Impact factor: 18.112

2.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

3.  Depression and risk for onset of type II diabetes. A prospective population-based study.

Authors:  W W Eaton; H Armenian; J Gallo; L Pratt; D E Ford
Journal:  Diabetes Care       Date:  1996-10       Impact factor: 19.112

4.  Use of antidepressant agents and the risk of type 2 diabetes.

Authors:  S Khoza; J C Barner; T M Bohman; K Rascati; K Lawson; J P Wilson
Journal:  Eur J Clin Pharmacol       Date:  2011-11-26       Impact factor: 2.953

5.  Weight gain as a risk factor for clinical diabetes mellitus in women.

Authors:  G A Colditz; W C Willett; A Rotnitzky; J E Manson
Journal:  Ann Intern Med       Date:  1995-04-01       Impact factor: 25.391

6.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

7.  Central 5-hydroxytryptamine2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat.

Authors:  F Chaouloff; S H Gunn; J B Young
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

8.  Hyperglycemia induced by acute central fluoxetine administration: role of the central CRH system and 5-HT3 receptors.

Authors:  F Carvalho; D Barros; J Silva; E Rezende; M Soares; J Fregoneze; E De Castro e Silva
Journal:  Neuropeptides       Date:  2004 Apr-Jun       Impact factor: 3.286

9.  Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

Authors:  J M Chan; E B Rimm; G A Colditz; M J Stampfer; W C Willett
Journal:  Diabetes Care       Date:  1994-09       Impact factor: 19.112

10.  Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.

Authors:  Frank Andersohn; René Schade; Samy Suissa; Edeltraut Garbe
Journal:  Am J Psychiatry       Date:  2009-04-01       Impact factor: 18.112

View more
  21 in total

1.  Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase®.

Authors:  Thi Thu Ha Nguyen; Anne Roussin; Vanessa Rousseau; Jean-Louis Montastruc; François Montastruc
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  Depression Treatment Among Elderly Medicare Beneficiaries With Incident Cases of Cancer and Newly Diagnosed Depression.

Authors:  Monira Alwhaibi; Suresh Madhavan; Thomas Bias; Kimberly Kelly; Jamie Walkup; Usha Sambamoorthi
Journal:  Psychiatr Serv       Date:  2017-01-03       Impact factor: 3.084

3.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

4.  Antidepressant continuation in pregnancy and risk of gestational diabetes.

Authors:  Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-12       Impact factor: 2.890

5.  Cumulative childhood adversity and adult cardiometabolic disease: A meta-analysis.

Authors:  Karen P Jakubowski; Jenny M Cundiff; Karen A Matthews
Journal:  Health Psychol       Date:  2018-08       Impact factor: 4.267

6.  Association between major depression and type 2 diabetes in midlife: findings from the Screening Across the Lifespan Twin Study.

Authors:  Briana Mezuk; Victor Heh; Elizabeth Prom-Wormley; Kenneth S Kendler; Nancy L Pedersen
Journal:  Psychosom Med       Date:  2015-06       Impact factor: 4.312

7.  Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.

Authors:  Yane Costa Chaves; Karina Genaro; José Alexandre Crippa; Joice Maria da Cunha; Janaína Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2021-01-19       Impact factor: 3.584

8.  Sexual violence and cardiovascular disease risk: A systematic review and meta-analysis.

Authors:  Karen P Jakubowski; Vanessa Murray; Natalie Stokes; Rebecca C Thurston
Journal:  Maturitas       Date:  2021-08-04       Impact factor: 4.342

9.  Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease.

Authors:  Mayank Ajmera; Chan Shen; Usha Sambamoorthi
Journal:  Popul Health Manag       Date:  2016-09-30       Impact factor: 2.459

10.  Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents.

Authors:  Jenny W Sun; Sonia Hernández-Díaz; Sebastien Haneuse; Florence T Bourgeois; Seanna M Vine; Mark Olfson; Brian T Bateman; Krista F Huybrechts
Journal:  JAMA Psychiatry       Date:  2021-01-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.